Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

ClinicalTrials.gov ID: NCT04865887

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04865887. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.

Study identification

NCT ID: NCT04865887
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Georgetown University; Other
Enrollment: 35 participants

Conditions and interventions

Conditions

Interventions

Pembrolizumab Drug
Lenvatinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 7, 2022 (Actual)
Primary completion: Dec 2027 (Estimated)
Completion: Jul 2028 (Estimated)
Last update posted: Sep 10, 2026

2022 – 2028

United States locations

U.S. sites: 4
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
MedStar Georgetown University Hospital	Washington D.C.	District of Columbia	20007	Recruiting
Medstar Washington Hospital Center	Washington D.C.	District of Columbia	20010	Withdrawn
Georgia Cancer Center at Augusta University	Augusta	Georgia	30912	Recruiting
John Theurer Cancer Center at Hackensack UMC	Hackensack	New Jersey	07601	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04865887, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 10, 2026 · Synced Nov 13, 2026